Human pharmacokinetics of the antiviral drug DHPG

Courtney Fletcher, Ronald Sawchuk, Barbara Chinnock, Paulo de Miranda, Henry H. Balfour

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

The pharmacokinetics of the antiviral drug 9-[2-hydroxy-l-(hydroxymethyl) ethoxymethyl]guanine (DHPG) were examined in six patients receiving 2.5 or 5.0 mg/kg every 8 or 12 hours for human cytomegalovirus (HCMV) pneumonitis or retinitis. Biexponential decay with a mean distribution t 1 2 of 0.23 hours and terminal t 1 2 of 2.53 hours was observed. Total clearance correlated well with and exceeded creatinine clearance by a factor of 2.4. Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2. Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 μg/ml and <0.25 to 0.63 μg/ml, respectively, in patients receiving 2.5 mg/kg. Peak concentrations are well above those needed to inhibit HCMV at the 50% level (ID50) and troughs are near this ID50. Cerebrospinal fluid concentrations of DHPG indicate a penetration of 24% to 67%. No accumulation of DHPG was apparent in these patients. However, dosage reduction is necessary in renal insufficiency. Neutropenia occurred in one patient. The plasma concentration profile of DHPG suggests potential beneficial activity against HCMV.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume40
Issue number3
DOIs
StatePublished - Sep 1986

Fingerprint

Antiviral Agents
Pharmacokinetics
Cytomegalovirus
Retinitis
Guanine
Neutropenia
Human Activities
Renal Insufficiency
Cerebrospinal Fluid
Creatinine
Pneumonia
dihydroxyphenylethylene glycol

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Human pharmacokinetics of the antiviral drug DHPG. / Fletcher, Courtney; Sawchuk, Ronald; Chinnock, Barbara; de Miranda, Paulo; Balfour, Henry H.

In: Clinical Pharmacology and Therapeutics, Vol. 40, No. 3, 09.1986, p. 281-286.

Research output: Contribution to journalArticle

Fletcher, C, Sawchuk, R, Chinnock, B, de Miranda, P & Balfour, HH 1986, 'Human pharmacokinetics of the antiviral drug DHPG', Clinical Pharmacology and Therapeutics, vol. 40, no. 3, pp. 281-286. https://doi.org/10.1038/clpt.1986.177
Fletcher, Courtney ; Sawchuk, Ronald ; Chinnock, Barbara ; de Miranda, Paulo ; Balfour, Henry H. / Human pharmacokinetics of the antiviral drug DHPG. In: Clinical Pharmacology and Therapeutics. 1986 ; Vol. 40, No. 3. pp. 281-286.
@article{035efeaa2d9b44d9a5cccdaaa956e6c1,
title = "Human pharmacokinetics of the antiviral drug DHPG",
abstract = "The pharmacokinetics of the antiviral drug 9-[2-hydroxy-l-(hydroxymethyl) ethoxymethyl]guanine (DHPG) were examined in six patients receiving 2.5 or 5.0 mg/kg every 8 or 12 hours for human cytomegalovirus (HCMV) pneumonitis or retinitis. Biexponential decay with a mean distribution t 1 2 of 0.23 hours and terminal t 1 2 of 2.53 hours was observed. Total clearance correlated well with and exceeded creatinine clearance by a factor of 2.4. Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2. Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 μg/ml and <0.25 to 0.63 μg/ml, respectively, in patients receiving 2.5 mg/kg. Peak concentrations are well above those needed to inhibit HCMV at the 50{\%} level (ID50) and troughs are near this ID50. Cerebrospinal fluid concentrations of DHPG indicate a penetration of 24{\%} to 67{\%}. No accumulation of DHPG was apparent in these patients. However, dosage reduction is necessary in renal insufficiency. Neutropenia occurred in one patient. The plasma concentration profile of DHPG suggests potential beneficial activity against HCMV.",
author = "Courtney Fletcher and Ronald Sawchuk and Barbara Chinnock and {de Miranda}, Paulo and Balfour, {Henry H.}",
year = "1986",
month = "9",
doi = "10.1038/clpt.1986.177",
language = "English (US)",
volume = "40",
pages = "281--286",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Human pharmacokinetics of the antiviral drug DHPG

AU - Fletcher, Courtney

AU - Sawchuk, Ronald

AU - Chinnock, Barbara

AU - de Miranda, Paulo

AU - Balfour, Henry H.

PY - 1986/9

Y1 - 1986/9

N2 - The pharmacokinetics of the antiviral drug 9-[2-hydroxy-l-(hydroxymethyl) ethoxymethyl]guanine (DHPG) were examined in six patients receiving 2.5 or 5.0 mg/kg every 8 or 12 hours for human cytomegalovirus (HCMV) pneumonitis or retinitis. Biexponential decay with a mean distribution t 1 2 of 0.23 hours and terminal t 1 2 of 2.53 hours was observed. Total clearance correlated well with and exceeded creatinine clearance by a factor of 2.4. Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2. Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 μg/ml and <0.25 to 0.63 μg/ml, respectively, in patients receiving 2.5 mg/kg. Peak concentrations are well above those needed to inhibit HCMV at the 50% level (ID50) and troughs are near this ID50. Cerebrospinal fluid concentrations of DHPG indicate a penetration of 24% to 67%. No accumulation of DHPG was apparent in these patients. However, dosage reduction is necessary in renal insufficiency. Neutropenia occurred in one patient. The plasma concentration profile of DHPG suggests potential beneficial activity against HCMV.

AB - The pharmacokinetics of the antiviral drug 9-[2-hydroxy-l-(hydroxymethyl) ethoxymethyl]guanine (DHPG) were examined in six patients receiving 2.5 or 5.0 mg/kg every 8 or 12 hours for human cytomegalovirus (HCMV) pneumonitis or retinitis. Biexponential decay with a mean distribution t 1 2 of 0.23 hours and terminal t 1 2 of 2.53 hours was observed. Total clearance correlated well with and exceeded creatinine clearance by a factor of 2.4. Mean volume of the central compartment was 15.26 L/1.73 m2 and the volume of distribution at steady state was 32.8 L/1.73 m2. Peak (model predicted) and trough plasma concentrations were 4.75 to 6.20 μg/ml and <0.25 to 0.63 μg/ml, respectively, in patients receiving 2.5 mg/kg. Peak concentrations are well above those needed to inhibit HCMV at the 50% level (ID50) and troughs are near this ID50. Cerebrospinal fluid concentrations of DHPG indicate a penetration of 24% to 67%. No accumulation of DHPG was apparent in these patients. However, dosage reduction is necessary in renal insufficiency. Neutropenia occurred in one patient. The plasma concentration profile of DHPG suggests potential beneficial activity against HCMV.

UR - http://www.scopus.com/inward/record.url?scp=0022551586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022551586&partnerID=8YFLogxK

U2 - 10.1038/clpt.1986.177

DO - 10.1038/clpt.1986.177

M3 - Article

C2 - 3017630

AN - SCOPUS:0022551586

VL - 40

SP - 281

EP - 286

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -